VPTDF (VentriPoint Diagnostics) Beta: 0.5309 (As of Jun. 26, 2026)


VPTDF VentriPoint Diagnostics Ltd VPTDF
6 GF Score
Price $0.08
! 4 Warning Signs
View Full Analysis

What is VentriPoint Diagnostics Beta?

VentriPoint Diagnostics VPTDF 6 Beta is 0.5309 as of Jun. 26, 2026. GuruFocus rates VPTDF with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), VentriPoint Diagnostics's Beta is 0.5309.


VentriPoint Diagnostics  (OTCPK:VPTDF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


VentriPoint Diagnostics Beta Related Terms


VentriPoint Diagnostics Beta Historical Data

* Premium members only.

The historical data trend for VentriPoint Diagnostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VentriPoint Diagnostics Beta Chart

VentriPoint Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -468.90 -249.97 1.45 1.42 0.47

VentriPoint Diagnostics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 0.64 0.37 0.57 0.47

VPTDF vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, VentriPoint Diagnostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VentriPoint Diagnostics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Beta distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's Beta falls into.


VPTDF
6GF Score
VentriPoint Diagnostics Ltd VPTDF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VentriPoint Diagnostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5309 mean?
VentriPoint Diagnostics (VPTDF) has a Beta of 0.5309 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for VentriPoint Diagnostics and its competitors.
Is VentriPoint Diagnostics' Beta too high?
VentriPoint Diagnostics' current Beta is 0.5309. Overall, VentriPoint Diagnostics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' Beta compare to ABT and SYK?
VentriPoint Diagnostics' Beta of 0.5309 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current Beta is 0.5309. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Beta of 0.5309. The current Beta is 0.5309. VentriPoint Diagnostics' overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Beta is 0.5309 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
6GF Score

Get the complete analysis for VPTDF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price